Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Waz, Piotr" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
Legitimacy and potential savings in automatic substitution of biological products in Poland, the example of insulin
Autorzy:
Wąż, Piotr
Gruchała, Katarzyna A.
Zimmermann, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/895667.pdf
Data publikacji:
2018-10-31
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
biologics
biosimilars
substitution
Opis:
Currently in Poland there is no regulation aiming at framing the complexity of substitution process arising at pharmacy level. In practice such process exists in variety type of products, both generic and biological scope. Lack of integrity in terms of this process between authorised medical professions who held it, might lead to further costs both for the health care system and patients. The aim of the study is to explain, that the economic advantage, which very often is the result of performed substitution process, in some types of products such as bio-logical ones, should be preceded with the decision of the treating physi-cian. Only then, in the cooperation between persons prescribing and dispensing certain medicinal product the process of substitution may fully use its potential of money saving along with the control over a certain patient. The study brings the yet unknown classification of dif-ferences in costs between actually performed automatic substitution of products containing human insulin in the pharmacy setting in Poland in four year period in five Voivodeships.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 5; 1255-1263
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Legal and economic identification and assessment of pharmacy substitution in narrow therapeutic index drugs, on the example of epileptic medications in Poland
Autorzy:
Zimmermann, Agnieszka
Gruchała, Katarzyna
Wąż, Piotr
Kawczak, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/895513.pdf
Data publikacji:
2018-12-31
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
pharmacy substitution
carbamazepine
pharmacy law
Opis:
Currently in Poland there is neither regulation aiming at framing the complexity of substitution process arising at pharmacy level, nor further guidelines depending on drug category. FDA describes a narrow therapeutic index drug (NTI) in the 21 Code of Federal Regulations 320.33(c) and highlights that safe and effective use of such drug products require careful titration and patient monitoring. In major therapeutic areas disadvantages of the generic substitution are irrelevant or minor in comparison to the economic benefit. In epilepsy, a number of experts and professional bodies have recommended caution with generic substitution of drugs used in this condition. Aim of the study is to legally and economically identify and assess drug sub-stitution occurrence in Polish background among selected narrow therapeutic index drugs used in epilepsy. Paper is divided into two sections: first is retrospective based and tackles the data received from the National Health Fund; whereas second section takes under consideration questionnaire based results gained during medical history being collect-ed with the patients. Basing on most commonly substituted substance in epilepsy: carbamazepine, the maximum single difference in cost in substitution at the pharmacy was identified around the level of 1.7 PLN, and maximum extra pay at the same level. Ob-served/reported changes, ADRs, discomfort were provided based on the question-naire. The study highlights the necessity of planning process and evaluation of cur-rent market regulations.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1447-1458
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
A policy view: gaps and weaknesses of substitution between biological products in law and economics dimension: the example of insulin
Autorzy:
Gruchała, Katarzyna A.
Waz, Piotr
Kawczak, Piotr
Zimmermann, Agnieszka
Wolnik, Bogumił
Baczek, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/895366.pdf
Data publikacji:
2018-08-31
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
insulin
biosimilars
substitution
drug policy
legilation
Opis:
The purpose of the study is to analyze the act of substitution between biological products. Diabetes mellitus notes the greatest increase in the projected causes of deaths globally till 2030. The proper drug substitution process may help to increase the control over the disease management. In this paper authors try to identify and explain the challenges for the health policies and legislations in emerging markets and low- and middle-income countries. Analysis of retrospective data covering prescribed-dispensed insulin products was performed. The study is based on the law and economics approach with the application of the planning theory and modeling. The study shows the scope of substitution process of insulin and highlights the necessity of univocal legal approach profiled for this therapy area. Prognosis of created base model indicates at constant presence of substitution process of insulin. Substitution is to bring financial savings for patients, it is yet however unknown whether savings arising from the act of purchase will still have positive impact on undertaken therapy process in long-term period. These findings may inform about important factors and how emerging markets and low- and middle-income countries can increase progress of the substitution process.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 4; 1003-1015
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies